TY - JOUR
T1 - Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia
AU - Shanafelt, Tait
AU - Zent, Clive
AU - Byrd, John
AU - Erlichman, Charles
AU - Laplant, Betsy
AU - Ghosh, Asish
AU - Call, Timothy
AU - Villalona-Calero, Miguel
AU - Jelinek, Diane
AU - Bowen, Deborah
AU - Laumann, Kristina
AU - Wu, Wenting
AU - Hanson, Curtis
AU - Kay, Neil
N1 - Funding Information:
from the National Institutes of Health (NIH), National Cancer Institute (NCI) CA113408, CA116237, N01-CM62205; CA25224; CA114740, CA15083, N01-CM62207, the Commonwealth Foundation for Cancer Research, and Polyphenon E International are gratefully acknowledged. Study sponsors had no input in the study design, collection/ analysis/interpretation of data, writing of the manuscript; or decision to submit the manuscript for publication.
PY - 2010/12
Y1 - 2010/12
N2 - Between 2005 and 2008, we conducted separate phase II clinical testing of three distinct anti-VEGF therapies for patients with relapsed/refractory CLL. Collectively, 46 patients were accrued to trials of single-agent anti-VEGF antibody (bevacizumab, n = 13) or one of two receptor tyrosine kinase inhibitors (AZD2171, n = 15; sunitinib malate, n = 18). All patients have completed treatment. Patients received a median of two cycles of bevacizumab, AZD2171, or sunitinib malate. All three trials were closed early due to lack of efficacy. No complete or partial remissions were observed. Individually and collectively, these studies indicate that single-agent anti-VEGF therapy has minimal clinical activity for patients with relapsed/refractory CLL.
AB - Between 2005 and 2008, we conducted separate phase II clinical testing of three distinct anti-VEGF therapies for patients with relapsed/refractory CLL. Collectively, 46 patients were accrued to trials of single-agent anti-VEGF antibody (bevacizumab, n = 13) or one of two receptor tyrosine kinase inhibitors (AZD2171, n = 15; sunitinib malate, n = 18). All patients have completed treatment. Patients received a median of two cycles of bevacizumab, AZD2171, or sunitinib malate. All three trials were closed early due to lack of efficacy. No complete or partial remissions were observed. Individually and collectively, these studies indicate that single-agent anti-VEGF therapy has minimal clinical activity for patients with relapsed/refractory CLL.
KW - Chronic lymphocytic leukemia
KW - angiogenesis
KW - bevacizumab
KW - receptor tyrosine kinase inhibitor
KW - therapy
KW - vascular endothelial growth factor (VEGF)
UR - http://www.scopus.com/inward/record.url?scp=78650070633&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78650070633&partnerID=8YFLogxK
U2 - 10.3109/10428194.2010.524327
DO - 10.3109/10428194.2010.524327
M3 - Article
C2 - 21054149
AN - SCOPUS:78650070633
SN - 1042-8194
VL - 51
SP - 2222
EP - 2229
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 12
ER -